DE60333487D1 - Therapeutische retrovirus-vektoren für gentherapie - Google Patents

Therapeutische retrovirus-vektoren für gentherapie

Info

Publication number
DE60333487D1
DE60333487D1 DE60333487T DE60333487T DE60333487D1 DE 60333487 D1 DE60333487 D1 DE 60333487D1 DE 60333487 T DE60333487 T DE 60333487T DE 60333487 T DE60333487 T DE 60333487T DE 60333487 D1 DE60333487 D1 DE 60333487D1
Authority
DE
Germany
Prior art keywords
gene therapy
hematopoietic
retrovirus vectors
cells
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60333487T
Other languages
English (en)
Inventor
Philippe Leboulch
Robert Pawliuk
Karen Westerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Bluebird Bio Inc
Original Assignee
Massachusetts Institute of Technology
Genetix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology, Genetix Pharmaceuticals Inc filed Critical Massachusetts Institute of Technology
Application granted granted Critical
Publication of DE60333487D1 publication Critical patent/DE60333487D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/40—Vector systems having a special element relevant for transcription being an insulator
DE60333487T 2002-12-13 2003-12-11 Therapeutische retrovirus-vektoren für gentherapie Expired - Lifetime DE60333487D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43332102P 2002-12-13 2002-12-13
US47582203P 2003-06-04 2003-06-04
US51331203P 2003-10-21 2003-10-21
PCT/US2003/039526 WO2004054512A2 (en) 2002-12-13 2003-12-11 Therapeutic retroviral vectors for gene therapy

Publications (1)

Publication Number Publication Date
DE60333487D1 true DE60333487D1 (de) 2010-09-02

Family

ID=32600914

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60333487T Expired - Lifetime DE60333487D1 (de) 2002-12-13 2003-12-11 Therapeutische retrovirus-vektoren für gentherapie

Country Status (9)

Country Link
US (6) US7901671B2 (de)
EP (1) EP1581056B1 (de)
AT (1) ATE474460T1 (de)
AU (1) AU2003296958A1 (de)
CY (1) CY1112327T1 (de)
DE (1) DE60333487D1 (de)
ES (1) ES2348868T3 (de)
HK (1) HK1082379A1 (de)
WO (1) WO2004054512A2 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1581056B1 (de) * 2002-12-13 2010-07-21 Genetix Pharmaceuticals Inc. Therapeutische retrovirus-vektoren für gentherapie
WO2007109583A2 (en) 2006-03-17 2007-09-27 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject
US20090144270A1 (en) * 2007-11-29 2009-06-04 Jack Thacher Leonard Methods for the prevention of diseases
GB0812191D0 (en) * 2008-07-03 2008-08-13 Greater Glasgow Health Board Modified cells and methods of monitoring their viability
ES2631458T3 (es) 2010-03-04 2017-08-31 Interna Technologies B.V. Molécula de ARNmi definida por su fuente y sus usos terapéuticos en el cáncer asociado a la EMT
CA2804599C (en) 2010-07-06 2023-01-31 Interna Technologies Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
EP2474617A1 (de) 2011-01-11 2012-07-11 InteRNA Technologies BV MIR zur Behandlung von Neoangiogenese
US9789139B2 (en) 2011-06-10 2017-10-17 Bluebird Bio, Inc. Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy
AU2011377617B2 (en) 2011-09-23 2018-03-08 Bluebird Bio, Inc. Improved gene therapy methods
KR102011532B1 (ko) 2011-09-30 2019-08-16 블루버드 바이오, 인코포레이티드. 개선된 바이러스 형질도입을 위한 화합물
US10174314B2 (en) 2011-12-22 2019-01-08 Interna Technologies B.V. MiRNA for treating head and neck cancer
EP2825048A4 (de) * 2012-03-13 2015-10-14 Anthrogenesis Corp Modifizierte erythrozytenvorläuferzellen und verwendungen davon
WO2014043131A1 (en) * 2012-09-14 2014-03-20 The Regents Of The University Of California Lentiviral vector for stem cell gene therapy of sickle cell disease
EP2917348A1 (de) 2012-11-06 2015-09-16 InteRNA Technologies B.V. Kombination zur behandlung von erkrankungen oder zuständen im zusammenhang mit melanom oder behandlung von erkrankungen und zuständen im zusammenhang mit aktivierten b-raf-signalweg
SG11201504038XA (en) 2012-11-27 2015-06-29 Childrens Medical Center Targeting bcl11a distal regulatory elements for fetal hemoglobin reinduction
WO2015073587A2 (en) 2013-11-18 2015-05-21 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
EP3125927B1 (de) 2014-04-01 2021-01-27 Rubius Therapeutics, Inc. Verfahren und zusammensetzungen zur immunmodulation
JP6514717B2 (ja) 2014-04-25 2019-05-15 ザ チルドレンズ メディカル センター コーポレーション 異常ヘモグロビン症を治療するための組成物および方法
FI3186395T4 (fi) * 2014-08-26 2023-05-25 Kantasolujen siirto kantasoluihin kohdistuvan aineen ja immunoregulatorisen signaloinnin modulaation yhdistelmällä
WO2016037163A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses
EP3191596B1 (de) 2014-09-11 2019-10-09 The U.S.A. as represented by the Secretary, Department of Health and Human Services Lentiviraler vektor zur behandlung von hämoglobinerkrankungen
AU2016209313B2 (en) * 2015-01-21 2021-10-14 Cornell University Viral vectors for prophylaxis and therapy of hemoglobinopathies
ES2835861T3 (es) 2015-05-08 2021-06-23 Childrens Medical Ct Corp Direccionamiento de regiones funcionales del potenciador de BCL11A para la reinducción de hemoglobina fetal
GB201600328D0 (en) 2016-01-08 2016-02-24 Univ Oslo Hf Anti-CD37 chimeric antigen receptors and immune cells expressing them
US11326183B2 (en) 2016-02-12 2022-05-10 Bluebird Bio, Inc. VCN enhancer compositions and methods of using the same
EP4151720A1 (de) 2016-02-12 2023-03-22 Bluebird Bio, Inc. Vcn-förderer-zusammensetzungen und verfahren zur verwendung davon
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CA3043768A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
AU2018205496A1 (en) 2017-01-07 2019-07-25 Selecta Biosciences, Inc. Patterned dosing of immunosuppressants coupled to synthetic nanocarriers
EP3574104A1 (de) 2017-01-30 2019-12-04 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Rekombinante virusvektoren zur behandlung der glykogenspeicherkrankheit
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
US11261441B2 (en) 2017-03-29 2022-03-01 Bluebird Bio, Inc. Vectors and compositions for treating hemoglobinopathies
WO2018218135A1 (en) 2017-05-25 2018-11-29 The Children's Medical Center Corporation Bcl11a guide delivery
WO2019075360A1 (en) 2017-10-13 2019-04-18 Selecta Biosciences, Inc. METHODS AND COMPOSITIONS FOR MITIGATING ANTI-VECTOR VIRAL TRANSFER IGM RESPONSES
US11497762B2 (en) 2017-11-03 2022-11-15 Interna Technologies B.V. MiRNA molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
KR20200139679A (ko) 2018-02-26 2020-12-14 안톨알엑스, 인크. 면역관용성 리포솜 및 그의 사용 방법
US11344008B1 (en) * 2018-03-11 2022-05-31 Hai Xing Chen Production of human DNaseI in erythrocytes of transgenic non-human mammal using erythroid-specific promoter
EP3806888B1 (de) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Von pde5 abgeleitete regulatorische konstrukte und verfahren zur verwendung in der immuntherapie
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
WO2020171889A1 (en) 2019-02-19 2020-08-27 University Of Rochester Blocking lipid accumulation or inflammation in thyroid eye disease
EP3935159A1 (de) 2019-03-08 2022-01-12 Obsidian Therapeutics, Inc. Menschliche carboanhydrase-2-zusammensetzungen und verfahren zur abstimmbaren regulierung
WO2020209934A1 (en) 2019-04-11 2020-10-15 Massachusetts Institute Of Technology Novel chimeric antigen receptors and libraries
CN114126666A (zh) 2019-04-28 2022-03-01 西莱克塔生物科技公司 用于治疗针对病毒转移载体具有预先存在的免疫力的对象的方法
EP3966227A1 (de) 2019-05-07 2022-03-16 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur vektorisierten vermehrung von proteinzerstörung, -expression und/oder -regulierung
CN114127305A (zh) 2019-05-23 2022-03-01 麻省理工学院 经由逆转录病毒表面展示的配体发现和基因递送
BR112021023594A2 (pt) 2019-05-28 2022-02-08 Selecta Biosciences Inc Métodos e composições para resposta imune de vetor de transferência antiviral atenuada
US20230092895A1 (en) 2019-08-30 2023-03-23 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
CN113046392B (zh) * 2019-12-27 2023-04-07 深圳市禾沐基因生物技术有限责任公司 治疗β-球蛋白功能缺失的重组慢病毒载体及制备方法和应用
WO2022235929A1 (en) 2021-05-05 2022-11-10 Radius Pharmaceuticals, Inc. Animal model having homologous recombination of mouse pth1 receptor
AU2022301302A1 (en) 2021-07-01 2024-01-25 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods
WO2023003844A1 (en) 2021-07-19 2023-01-26 2Seventy Bio, Inc. Vector manufacturing processes
WO2023019226A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
AU2022325231A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
AU2022325955A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
CA3227108A1 (en) 2021-08-11 2023-02-16 Xiaomeng HU Genetically modified primary cells for allogeneic cell therapy
WO2023047089A1 (en) 2021-09-21 2023-03-30 Oslo Universitetssykehus Hf Binding proteins for terminal deoxynucleotidyl transferase (tdt)
WO2023064367A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023114918A1 (en) 2021-12-16 2023-06-22 Ludwig Institute For Cancer Research Ltd Antisense transfer vectors and methods of use thereof
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023158836A1 (en) 2022-02-17 2023-08-24 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
WO2023173123A1 (en) 2022-03-11 2023-09-14 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
CN114457119B (zh) * 2022-04-11 2022-08-12 中吉智药(南京)生物技术有限公司 慢病毒载体在制备治疗β-地中海贫血药物中的应用
WO2024007020A1 (en) 2022-06-30 2024-01-04 Indapta Therapeutics, Inc. Combination of engineered natural killer (nk) cells and antibody therapy and related methods
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024050450A1 (en) 2022-08-31 2024-03-07 Gigamune, Inc. Engineered enveloped vectors and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6498294A (en) * 1993-04-07 1994-10-24 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Dna sequence which acts as a chromatin insulator element to protect expressed genes from (cis)-acting regulatory sequences in mammalian cells
EP0783575B1 (de) * 1994-09-19 1999-06-16 Massachusetts Institute Of Technology Anti-sickling beta-globin,zusammensetzung und verfahren zur behandlung von sichelzellanämie
WO1998017684A2 (en) * 1996-10-25 1998-04-30 Advanced Research & Technology Institute Dna sequences encoding fusions of dna repair proteins and uses thereof
US6531123B1 (en) * 1997-05-01 2003-03-11 Lung-Ji Chang Lentiviral vectors
US6136597A (en) * 1997-09-18 2000-10-24 The Salk Institute For Biological Studies RNA export element
AU1128400A (en) * 1998-10-22 2000-05-08 Medical College Of Georgia Institute, Inc. Long terminal repeat, enhancer, and insulator sequences for use in recombinant vectors
WO2002083080A2 (en) 2001-04-17 2002-10-24 Genetix Pharmaceuticals, Inc. Method of treating arthritis using lentiviral vectors in gene therapy
US20040033604A1 (en) 2001-04-20 2004-02-19 Gary Kobinger Recombinant lentiviral vectors pseudotyped in envelopes containing filovirus binding domains
WO2002087341A1 (en) * 2001-05-01 2002-11-07 Genetix Pharmaceuticals, Inc. Novel self-inactivating (sin) lentiviral vectors
IL161229A0 (en) * 2001-10-02 2004-09-27 Inst Clayton De La Rech Methods and compositions relating to restricted expression lentiviral vectors and their applications.
EP1581056B1 (de) 2002-12-13 2010-07-21 Genetix Pharmaceuticals Inc. Therapeutische retrovirus-vektoren für gentherapie

Also Published As

Publication number Publication date
US10632212B2 (en) 2020-04-28
US11701435B2 (en) 2023-07-18
US20120009161A1 (en) 2012-01-12
AU2003296958A8 (en) 2004-07-09
HK1082379A1 (en) 2006-06-09
ATE474460T1 (de) 2010-08-15
US10105451B2 (en) 2018-10-23
WO2004054512A3 (en) 2005-01-06
US20200368370A1 (en) 2020-11-26
EP1581056A4 (de) 2007-01-17
US20110274669A1 (en) 2011-11-10
EP1581056B1 (de) 2010-07-21
CY1112327T1 (el) 2015-12-09
AU2003296958A1 (en) 2004-07-09
US9068199B2 (en) 2015-06-30
EP1581056A2 (de) 2005-10-05
US20190038775A1 (en) 2019-02-07
US7901671B2 (en) 2011-03-08
ES2348868T3 (es) 2010-12-16
US20060057725A1 (en) 2006-03-16
US20160022839A1 (en) 2016-01-28
WO2004054512A2 (en) 2004-07-01

Similar Documents

Publication Publication Date Title
ATE474460T1 (de) Therapeutische retrovirus-vektoren für gentherapie
MXPA05007822A (es) Terapia de combinacion para tratar trastornos de la deficiencia de proteinas.
WO2002064748A8 (en) Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
EP1832598A3 (de) Therapeutische Behandlung von androgenrezeptorbedingten Leiden
AU2003303384A8 (en) Uses of mammalian cytokine; related reagents
ATE524554T1 (de) Nicht integrativer und nicht replikativer lentivirus, herstellung und verwendungen
DE60231439D1 (de) Mitotische kinesinhemmer
DE60234278D1 (de) Mitotische kinesin-hemmer
MX2007004551A (es) Compuestos tiadiazol y metodos de uso.
ATE372341T1 (de) Inhibitoren von mitotischem kinesin
DE60324449D1 (de) Inhibitoren der phosphodiesterase der zyklischen n, und deren verwendung in therapie
ATE211392T1 (de) Verwendung des glialen, neurotrophen faktors (gdnf) zur behandlung von gehörstörungen
MXPA02007099A (es) Compuestos de tiazola, imidazola y oxazola y tratamientos de desordenes asociados con la maduracion de la proteina.
PL356846A1 (en) Use of interleukin-6 antagonists for the treatment of diseases characterised by high levels of aromatase
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
ZA200609220B (en) Method of treating dry eye disorders and uveitis
TR200102985T2 (tr) Gen tedavisi teknikleri.
ATE321566T1 (de) Verwendung von long pentraxin ptx3 für die behandlung von infertilität bei frauen
ATE287722T1 (de) Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
EP1594485A4 (de) Zusammensetzungen mit substituierten chinolinen und substituierten diphenylsulfonen sowie verwendungsverfahren
TW200503693A (en) 4-, 6- or 7-hydroxyindoles with n-oxide groups and the use thereof as therapeutic agents
MX2021014028A (es) Métodos y composiciones para tratar obesidad y/o trastornos de la piel.
WO2024044697A3 (en) Compositions and methods for treatment of fabry disease